Johnson & Johnson $JNJ Shares Sold by Wealthspire Advisors LLC

Wealthspire Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 170,094 shares of the company’s stock after selling 11,262 shares during the period. Wealthspire Advisors LLC’s holdings in Johnson & Johnson were worth $25,982,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Nuveen LLC acquired a new position in Johnson & Johnson in the 1st quarter worth $1,369,188,000. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.3% during the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Johnson & Johnson by 1,382.0% in the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after acquiring an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% in the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after purchasing an additional 2,557,388 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $401,420,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 0.3%

NYSE:JNJ opened at $200.10 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $186.69 and a 200-day moving average of $170.77. The firm has a market capitalization of $482.11 billion, a PE ratio of 19.31, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $200.30.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analysts Set New Price Targets

Several research firms have recently commented on JNJ. Sanford C. Bernstein increased their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. UBS Group raised their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Finally, Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.